JDOC vs. PBE

Last updated Aug 4, 2026

JDOC (Jpmorgan Healthcare Leaders ETF) and PBE (Invesco Dynamic Biotechnology & Genome ETF) are both Health & Biotech Equities funds. JDOC is actively managed, while PBE is passively managed. Over the past year, JDOC returned 23.57% vs 40.22% for PBE. Their 0.74 correlation means they have sometimes moved together and sometimes differently. JDOC charges 0.65%/yr vs 0.59%/yr for PBE.

Performance

JDOC vs. PBE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Jpmorgan Healthcare Leaders ETF (JDOC) and Invesco Dynamic Biotechnology & Genome ETF (PBE). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, JDOC achieves a 4.29% return, which is significantly lower than PBE's 10.93% return.

JDOC

• 1D: -0.50%
• 1M: -2.51%
• 6M: 2.15%
• YTD: 4.29%
• 1Y: 23.57%
• 3Y*: —
• 5Y*: —
• 10Y*: —
• ALL TIME*: 9.54%

PBE

• 1D: 0.61%
• 1M: -2.05%
• 6M: 10.13%
• YTD: 10.93%
• 1Y: 40.22%
• 3Y*: 14.50%
• 5Y*: 3.79%
• 10Y*: 8.05%
• ALL TIME*: 9.19%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison

Position	Avg. Volume Value (2W)	Avg. Volume Value (1M)	Avg. Volume Value (3M)
JDOC Jpmorgan Healthcare Leaders ETF	$21.20K	$19.99K	$31.46K
PBE Invesco Dynamic Biotechnology & Genome ETF	$6.69M	$3.57M	$1.57M

JDOC vs. PBE - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023
JDOC Jpmorgan Healthcare Leaders ETF	4.29%	15.36%	-1.04%	7.92%
PBE Invesco Dynamic Biotechnology & Genome ETF	10.93%	24.84%	1.10%	22.03%

Correlation

The correlation between JDOC and PBE is 0.80, which is moderate. They have sometimes moved together and sometimes differently, sharing some price drivers without tracking each other closely.

	Correlation
Correlation (1Y) Focuses on recent behavior, but can change the most.	0.80
Correlation (All Time) Calculated using the full available price history since Nov 2, 2023	0.74

The correlation between JDOC and PBE has been stable across timeframes, ranging from 0.74 to 0.80 - a consistent structural relationship.

JDOC vs. PBE - Sectors Allocation Comparison

Sectors	JDOC	PBE
Healthcare	100.0%	100.0%
Basic Materials	-	-
Communication Services	-	-
Consumer Cyclical	-	-
Consumer Defensive	-	-
Energy	-	-
Financial Services	-	0.1%
Industrials	-	-
Real Estate	-	-
Technology	-	-
Utilities	-	-

Return for Risk

JDOC vs. PBE — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

JDOC

JDOC Risk / Return Rank: 63
JDOC Sharpe Ratio Rank: 65
JDOC Sortino Ratio Rank: 73
JDOC Omega Ratio Rank: 61
JDOC Calmar Ratio Rank: 65
JDOC Martin Ratio Rank: 51

PBE

PBE Risk / Return Rank: 83
PBE Sharpe Ratio Rank: 87
PBE Sortino Ratio Rank: 89
PBE Omega Ratio Rank: 82
PBE Calmar Ratio Rank: 86
PBE Martin Ratio Rank: 74

The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

JDOC vs. PBE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Jpmorgan Healthcare Leaders ETF (JDOC) and Invesco Dynamic Biotechnology & Genome ETF (PBE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	JDOC	PBE	Difference
Sharpe ratio: Return per unit of total volatility	1.60	2.15	-0.55
Sortino ratio: Return per unit of downside risk	2.53	3.14	-0.61
Omega ratio: Gain probability vs. loss probability	1.28	1.36	-0.08
Calmar ratio: Return relative to maximum drawdown	2.44	3.44	-1.00
Martin ratio: Return relative to average drawdown	6.25	9.64	-3.39

JDOC vs. PBE - Sharpe Ratio Comparison

The current JDOC Sharpe Ratio is 1.60, which is comparable to the PBE Sharpe Ratio of 2.15. The chart below compares the historical Sharpe Ratios of JDOC and PBE, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

JDOC vs. PBE - Drawdown Comparison

The maximum JDOC drawdown since its inception was -20.87%, smaller than the maximum PBE drawdown of -45.69%. Use the drawdown chart below to compare losses from any high point for JDOC and PBE.

Drawdown Indicators

	JDOC	PBE	Difference
Max Drawdown Largest peak-to-trough decline	-20.87%	-45.69%	+24.82%
Max Drawdown (1Y) Largest decline over 1 year	-9.68%	-11.73%	+2.05%
Max Drawdown (3Y) Largest decline over 3 years	—	-22.43%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-34.71%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-37.84%	—
Current Drawdown Current decline from peak	-3.07%	-3.24%	+0.17%
Average Drawdown Average peak-to-trough decline	-6.72%	-16.12%	+9.40%
Ulcer Index Depth and duration of drawdowns from previous peaks	3.78%	4.18%	-0.40%

Volatility

JDOC vs. PBE - Volatility Comparison

The current volatility for Jpmorgan Healthcare Leaders ETF (JDOC) is 4.64%, while Invesco Dynamic Biotechnology & Genome ETF (PBE) has a volatility of 5.09%. This indicates that JDOC experiences smaller price fluctuations and is considered to be less risky than PBE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	JDOC	PBE	Difference
Volatility (1M) Calculated over the trailing 1-month period	4.64%	5.09%	-0.45%
Volatility (6M) Calculated over the trailing 6-month period	11.60%	13.55%	-1.95%
Volatility (1Y) Calculated over the trailing 1-year period	14.82%	18.85%	-4.03%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	14.69%	22.50%	-7.81%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	14.69%	24.73%	-10.04%

JDOC vs. PBE - Expense Ratio Comparison

JDOC has a 0.65% expense ratio, which is higher than PBE's 0.59% expense ratio.

Dividends

JDOC vs. PBE - Dividend Comparison

JDOC's dividend yield for the trailing twelve months is around 0.85%, less than PBE's 1.72% yield.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
JDOC Jpmorgan Healthcare Leaders ETF	0.85%	0.89%	5.57%	0.15%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
PBE Invesco Dynamic Biotechnology & Genome ETF	1.72%	1.00%	0.05%	0.02%	0.00%	0.00%	0.04%	0.00%	0.00%	0.57%	0.38%	1.12%

Frequently Asked Questions

Can I hold both JDOC and PBE in my portfolio?

JDOC and PBE have a correlation of 0.80, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, JDOC or PBE?

PBE has higher volatility (5.09%) compared to JDOC (4.64%). In terms of maximum drawdown, JDOC dropped -20.87% vs PBE's -45.69%.

Which ETF is better, JDOC or PBE?

On 1-year performance, PBE leads with 40.22% vs 23.57% for JDOC. On fees, PBE is cheaper at 0.59% per year. On volatility, JDOC has been the lower-risk option at 4.64%. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF has performed better, JDOC or PBE?

Over the 1-year period, PBE has performed better with a 40.22% return vs 23.57%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

Which ETF is cheaper, JDOC or PBE?

PBE is cheaper with a 0.59% expense ratio, compared with 0.65% for JDOC.

Which ETF pays a higher dividend yield, JDOC or PBE?

PBE has the higher dividend yield at 1.72%, compared with 0.85% for JDOC.

What is the main difference between JDOC and PBE?

They also come from different issuers: JPMorgan and Invesco. Their fees differ too: 0.65% for JDOC and 0.59% for PBE.

Which has better risk-adjusted returns?

PBE currently has the higher Sharpe Ratio (2.15 vs 1.60), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.